-
AstraZeneca announces positive results from ADRIATIC phase III trial of Imfinzi in patients with limited─stage small cell lung cancer
06 Apr 2024 05:12 GMT
… with Imfinzi in liver and lung cancers, the combination of Imjudo and … innovations, including Tagrisso (osimertinib) and Iressa (gefitinib); Imfinzi and Imjudo; Enhertu … meaningful improvements for people with lung cancer, including and beyond treatment.
…
-
AstraZeneca : Tagrisso with the addition of chemotherapy showed favourable trend in overall survival in EGFR-mutated advanced lung cancer with further follow up in FLAURA2 Phase III trial
21 Mar 2024 14:23 GMT
… of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer ( … stage setting.
Notes
Lung cancer
Lung cancer is the leading … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … for people with lung cancer, including and beyond …
-
AstraZeneca's Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, stage III EGFR─mutated lung cancer in LAURA phase III trial
20 Feb 2024 07:03 GMT
… -mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … meaningful improvements for people with lung cancer, including and beyond treatment.
…
-
Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
19 Feb 2024 08:27 GMT
… EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy … III trial.
Notes
Lung cancer
Lung cancer is the leading … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … for people with lung cancer, including and beyond …
-
AstraZeneca's Tagrisso with addition of chemotherapy approved in US for patients with EGFR─mutated advanced lung cancer
19 Feb 2024 08:21 GMT
… ) non-small cell lung cancer (NSCLC).
The approval … Lung cancer is broadly split into NSCLC and small cell lung cancer … lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa … for people with lung cancer, including and beyond …
-
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
17 Feb 2024 03:05 GMT
… clicking here
Notes
Lung cancer
Lung cancer is the leading … lung cancer medicines and the next wave of innovations, including TAGRISSO and IRESSA … for people with lung cancer, including and beyond … /lung-cancer-101/types-of-lung-cancer. Accessed …
-
Treatment with EGFR inhibitors in lung cancer patients tied to increased risk of new-onset keratitis: JAMA
16 Jan 2024 02:10 GMT
… -- including erlotinib (Tarceva), gefitinib (Iressa), afatinib (Gilotrif), and osimertinib ( … with lung cancer.
For this purpose, they examined TriNetX data of lung cancer … onset keratitis among patients with lung cancer receiving EGFRi treatment.
Based …
-
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions
23 Apr 2024 12:42 GMT
… 47;Paclitaxel in Asia” (IRESSA Pan-Asia Study; IPASS) … Non-Small Cell Lung Cancer Characterized by Epidermal … and molecular characteristics of lung cancers harboring EGFR exon … Patients With Non-Small Cell Lung Cancer (REZILIENT1). ClinicalTrials.Gov; …
-
Global Lung Cancer Drugs Market Forecast 2024-2033 – Market Size, Drivers, Trends, And Competitors
27 Dec 2023 16:45 GMT
… Iressa, Other Drugs
• By Disease Type: Small cell lung cancer … used to treat lung cancer. Lung cancer is a … lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Small cell lung cancer … is a type of lung cancer …
-
EGFR Inhibitor Market to Accelerate Substantially During the Study Period (2020–2034) | DelveInsight
22 Apr 2024 17:00 GMT
… -mutated non-small cell lung cancer.
In October 2023, … particularly non-small cell lung cancer (NSCLC). The EGFR … specifically TARCEVA (erlotinib) and IRESSA (gefitinib), which have shown … of lung cancer, accounting for 80─90% of all lung cancer cases. …